Gender-specific Associations of the Brain-derived Neurotrophic Factor Val66Met Polymorphism with Neurocognitive and Clinical Features in Schizophrenia
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objective: To explore associations of the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism with cognitive functioning and psychopathology in patients with schizophrenia. Methods: We included 133 subjects meeting the DSM-IV criteria for schizophrenia who were in the post-acute stage of the disease. BDNF Val66Met genotypes were identified via polymerase chain reaction. The computerized neurocognitive function battery, Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS), Social and Occupational Functioning Scale (SOFAS), and the Subjective Well-being under Neuroleptic Treatment (SWN-K) were administered. Gender-stratified sub-analysis was also conducted to identify gender-specific patterns in the findings. Results: In male patients, no significant difference in any measure by BDNF genotype was evident. In female patients, scores on the CDSS and total PANSS and all subscales were significantly higher in valine (Val) carriers. In addition, scores on the SOFAS and SWN-K were significantly lower in Val carriers. In terms of neurocognitive measures, female patients with the Val allele had significantly poorer reaction times and fewer correct responses on the Continuous Performance Test (CPT) and the Trail Making Test (Parts A and B). After adjustment of PANSS total scores and log-transformed CDSS scores, CPT outcomes were significantly poorer in female patients with than in those without the Val allele. Conclusion: Gender-specific associations of the Val allele with poor neurocognitive function and more severe psychopathology were evident. Further studies are required to explore the mechanisms of these differences and the potential utility of the BDNF genotype as a predictor of outcome in patients with schizophrenia.
Abstract
Objective: To explore associations of the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism with cognitive functioning and psychopathology in patients with schizophrenia. Methods: We included 133 subjects meeting the DSM-IV criteria for schizophrenia who were in the post-acute stage of the disease. BDNF Val66Met genotypes were identified via polymerase chain reaction. The computerized neurocognitive function battery, Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS), Social and Occupational Functioning Scale (SOFAS), and the Subjective Well-being under Neuroleptic Treatment (SWN-K) were administered. Gender-stratified sub-analysis was also conducted to identify gender-specific patterns in the findings. Results: In male patients, no significant difference in any measure by BDNF genotype was evident. In female patients, scores on the CDSS and total PANSS and all subscales were significantly higher in valine (Val) carriers. In addition, scores on the SOFAS and SWN-K were significantly lower in Val carriers. In terms of neurocognitive measures, female patients with the Val allele had significantly poorer reaction times and fewer correct responses on the Continuous Performance Test (CPT) and the Trail Making Test (Parts A and B). After adjustment of PANSS total scores and log-transformed CDSS scores, CPT outcomes were significantly poorer in female patients with than in those without the Val allele. Conclusion: Gender-specific associations of the Val allele with poor neurocognitive function and more severe psychopathology were evident. Further studies are required to explore the mechanisms of these differences and the potential utility of the BDNF genotype as a predictor of outcome in patients with schizophrenia.
참고문헌 (55)
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders" (2013), American Psychiatric Publishing
- Notaras M, "A role for the BDNF gene Val66Met polymorphism in schizophrenia? A comprehensive review", Neurosci Biobehav Rev, 51, pp.15~30 (2015)
- Guillin O, "BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization", Nature, 411, pp.86~89 (2001)
- Baker SA, "Maturation but not survival of dopaminergic nigrostriatal neurons is affected in developing and aging BDNF-deficient mice", Brain Res, 1039, pp.177~188 (2005)
- Guillin O, "Brain-derived neurotrophic factor and the plasticity of the mesolimbic dopamine pathway", Int Rev Neurobiol, 59, pp.425~444 (2004)
- Egan MF, "The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function", Cell, 112, pp.257~269 (2003)
- Bueller JA, "BDNF Val66Met allele is associated with reduced hippocampal volume in healthy subjects", Biol Psychiatry, 59, pp.812~815 (2006)
- Dincheva I, "Impact of the BDNF Val66Met polymorphism on cognition: implications for behavioral genetics", Neuroscientist, 18, pp.439~451 (2012)
- Smith GN, "Hippocampal volume and the brain-derived neurotrophic factor Val66Met polymorphism in first episode psychosis", Schizophr Res, 134, pp.253~259 (2012)
- Ahmed AO, "Brain-derived neurotrophic factor (BDNF) and neurocognitive deficits in people with schizophrenia: a meta-analysis", Psychiatry Res, 226, pp.1~13 (2015)
- Xiu MH, "Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics", Prog Neuropsychopharmacol Biol Psychiatry, 33, pp.1508~1512 (2009)
- Pillai A, "Plasma BDNF levels vary in relation to body weight in females", PLoS One, 7, pp.e39358~ (2012)
- Lu W, "Association between BDNF Val66Met polymorphism and cognitive performance in antipsychotic-naïve patients with schizophrenia", J Mol Neurosci, 47, pp.505~510 (2012)
- Zhang XY, "Gender difference in association of cognition with BDNF in chronic schizophrenia", Psychoneuroendocrinology, 48, pp.136~146 (2014)
- Sohrabji F, "Estrogen-BDNF interactions:implications for neurodegenerative diseases", Front Neuroendocrinol, 27, pp.404~414 (2006)
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders" (1994), American Psychiatric Press Inc
- Patel MX, "How to compare doses of different antipsychotics: a systematic review of methods", Schizophr Res, 149, pp.141~148 (2013)
- Kay SR, "The positive and negative syndrome scale (PANSS) for schizophrenia", Schizophr Bull, 13, pp.261~276 (1987)
- 이중서, "한국판 양성 및 음성증후군 척도(Positive and Negative Syndrome Scale)의 신뢰도와 타당도", 신경정신의학, 40(6), pp.1090~1105 (2001), 대한신경정신의학회
- Addington D, "A depression rating scale for schizophrenics", Schizophr Res, 3, pp.247~251 (1990)
- 김용구, "한국어판 정신분열병의 캘거리 우울증 척도의 신뢰도 및 타당도 연구", 신경정신의학, 44(4), pp.446~455 (2005), 대한신경정신의학회
- Kim SW, "Diagnostic validity of assessment scales for depression in patients with schizophrenia", Psychiatry Res, 144, pp.57~63 (2006)
- Naber D, "Improvement of schizophrenic patients'subjective well-being under atypical antipsychotic drugs", Schizophr Res, 50, pp.79~88 (2001)
- 김성완, "단축형 항정신병약물치료 중 주관적 안녕감 척도의 표준화 연구", 대한정신약물학회지, 18(4), pp.221~230 (2007), 대한정신약물학회
- 하규섭, "한국 성인 인지기능 평가를 위한 전산화 검사도구의 개발과 표준화 과정 및 요인분석", 신경정신의학, 41(3) (2002), 대한신경정신의학회
- Rey A, "L’examen clinique en psychologie" (1964), Presses Universitaires de France
- 하규섭, "한국 성인 주의력 평가를 위한 전산화 도구의 개발과 표준화", 신경정신의학, 41(2) (2002), 대한신경정신의학회
- Heaton RK, "Wisconsin Card Sorting Test Manual", Psychological Assessment Resources, ~ (1993)
- Lezak MD, "Neuropsychological assessment" (1995), Oxford University Press
- Dempster E, "Association between BDNF val66met genotype and episodic memory", Am J Med Genet B Neuropsychiatr Genet, 134B, pp.73~75 (2005)
- Jovanovic JN, "Synapsins as mediators of BDNF-enhanced neurotransmitter release", Nat Neurosci, 3, pp.323~329 (2000)
- Goggi J, "Signalling pathways involved in the short-term potentiation of dopamine release by BDNF", Brain Res, 968, pp.156~161 (2003)
- Chung S, "Association among aggressiveness, neurocognitive function, and the Val66Met polymorphism of brain-derived neurotrophic factor gene in male schizophrenic patients", Compr Psychiatry, 51, pp.367~372 (2010)
- Hill RA, "Sex-dependent and regionspecific changes in TrkB signaling in BDNF heterozygous mice", Brain Res, 1384, pp.51~60 (2011)
- Foltynie T, "The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson's disease", J Neurol, 252, pp.833~838 (2005)
- Berchtold NC, "Estrogen and exercise interact to regulate brain-derived neurotrophic factor mRNA and protein expression in the hippocampus", Eur J Neurosci, 14, pp.1992~2002 (2001)
- Ivanova T, "Estrogen stimulates brain-derived neurotrophic factor expression in embryonic mouse midbrain neurons through a membranemediated and calcium-dependent mechanism", J Neurosci Res, 66, pp.221~230 (2001)
- Solum DT, "Estrogen regulates the development of brain-derived neurotrophic factor mRNA and protein in the rat hippocampus", J Neurosci, 22, pp.2650~2659 (2002)
- Białecka M, "BDNF G196A (Val66Met)polymorphism associated with cognitive impairment in Parkinson's disease", Neurosci Lett, 561, pp.86~90 (2014)
- Karege F, "Decreased serum brain-derived neurotrophic factor levels in major depressed patients", Psychiatry Res, 109, pp.143~148 (2002)
- Shimizu E, "Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants", Biol Psychiatry, 54, pp.70~75 (2003)
- Dell'Osso L, "Associations between brain-derived neurotrophic factor plasma levels and severity of the illness, recurrence and symptoms in depressed patients", Neuropsychobiology, 62, pp.207~212 (2010)
- Sun MM, "BDNF Val66Met polymorphism and anxiety", depression symptoms in schizophrenia in a Chinese Han population, 2013, pp.23, 124~129
- Kreinin A, "Blood BDNF level is gender specific in severe depression", PLoS One, 10, pp.e0127643~ (2015)
- Shalev I, "BDNF Val66Met polymorphism is associated with HPA axis reactivity to psychological stress characterized by genotype and gender interactions", Psychoneuroendocrinology, 34, pp.382~388 (2009)
- Alexander N, "The BDNF Val66Met polymorphism affects HPA-axis reactivity to acute stress", Psychoneuroendocrinology, 35, pp.949~953 (2010)
- Lang UE, "Association of a functional BDNF polymorphism and anxiety-related personality traits", Psychopharmacology (Berl), 180, pp.95~99 (2005)
- Sen S, "A BDNF coding variant is associated with the NEO personality inventory domain neuroticism, a risk factor for depression", Neuropsychopharmacology, 28, pp.397~401 (2003)
- Zhang JP, "Genetic variation in BDNF is associated with antipsychotic treatment resistance in patients with schizophrenia", Schizophr Res, 146, pp.285~288 (2013)
- Suchanek R, "BDNF val66met polymorphism is associated with age at onset and intensity of symptoms of paranoid schizophrenia in a Polish population", J Neuropsychiatry Clin Neurosci, 25, pp.88~94 (2013)
- Zhou DH, "The study of BDNF Val66Met polymorphism in Chinese schizophrenic patients", Prog Neuropsychopharmacol Biol Psychiatry, 34, pp.930~933 (2010)
- Hashim HM, "Brain-derived neurotrophic factor Val66Met polymorphism and obsessive-compulsive symptoms in Egyptian schizophrenia patients", J Psychiatr Res, 46, pp.762~766 (2012)
- Numata S, "Brain-derived neurotrophic factor (BDNF)Val66Met polymorphism in schizophrenia is associated with age at onset and symptoms", Neurosci Lett, 401, pp.1~5 (2006)
- Zintzaras E, "Brain-derived neurotrophic factor gene polymorphisms and schizophrenia: a meta-analysis", Psychiatr Genet, 17, pp.69~75 (2007)
- Kim JM, "BDNF genotype potentially modifying the association between incident stroke and depression", Neurobiol Aging, 29, pp.789~792 (2008)